Akari Therapeutics (AKTX) Common Equity (2011 - 2026)

Akari Therapeutics has disclosed Common Equity across 16 years of filings, most recently posting $14.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $14.4 million, down 33.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (down 33.87% YoY), and the FY2025 annual result was $28.3 million, up 27.44% from the prior year.
• Common Equity came in at $14.4 million for Q1 2026 at Akari Therapeutics, down from $28.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $28.3 million in Q4 2025 to a low of -$6.7 million in Q3 2024.
• The 5-year median for Common Equity is $4.7 million (2023), against an average of $9.4 million.
• Peak annual rise in Common Equity reached 9806.99% in 2024, while the deepest fall reached 3242.72% in 2024.
• Akari Therapeutics' Common Equity stood at $1.8 million in 2022, then slumped by 112.79% to -$229000.0 in 2023, then surged by 9806.99% to $22.2 million in 2024, then gained by 27.44% to $28.3 million in 2025, then sank by 49.24% to $14.4 million in 2026.
• The last three Common Equity figures came in at $14.4 million (Q1 2026), $28.3 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.